Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.
Survival in newly diagnosed multiple myeloma improved significantly in patients who underwent early autologous stem cell transplantation (ASCT), according to pooled data from two randomized trials.
The 4-year overall survival was 85% in patients who underwent stem cell transplantation as consolidation therapy versus 76% for those who had transplants after first relapse, reported Federica Cavallo, MD, PhD, of the University of Torino in Italy, and colleagues.
Median time to first progression (PFS1) was almost twice as long in patients who had early stem cell transplantation, and the time to second relapse also was significantly delayed by early transplantation, they said at the European Hematology Association meeting.
Read the original report here: http://bit.ly/V5ycMW
Source: Medpage Today
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen